

## INFORMATION DISCLOSURE STATEMENT

**Applicant** 

Goddard et al.

App. No

10/063,587

Filed

May 3, 2002

For

SECRETED AND TRANSMEMBRANE

POLYPEPTIDES AND NUCLEIC ACIDS

**ENCODING THE SAME** 

Examiner

Claire M. Kaufman

Art Unit

1646

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

April 1, 2005

(Date)

AnneMarie Kaiser, Reg. No. 37,649

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 27 references to be considered by the Examiner. Also enclosed are 14 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed within three months of the filing date, with an RCE or before receipt of a first office action after an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

By: Morio K

AnneMarie Kaiser

Registration No. \$7,649 Attorney of Record

Customer No. 30313

(619) 235-8550

1528857\_1 033105

APR 0 4 2005 RMATION DISCLOS Spolication No. 10/063,587 Filing Date May 3, 2002 First Named Inventor Goddard et al. MENT BY APPLICANT 1646 Art Unit Claire M. Kaufman Examiner atiple sheets used when necessary) Attorney Docket No. GNE.3230R1C61 SHEET 1 OF 2

	U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
	1	6,025,156	02-15-2000	Gwynn, et al.		
	2	6,124,433	09-26-2000	Falb, et al.		
	3	6,156,500	12-05-2000	Falb, Dean		
-	4	6,162,604	12-19-2000	Jacob, Chaim O.		
	5	6,228,582	05-08-2001	Rodier, et al.		
	6	6,395,306	05-28-2002	Cui, et al.		
	7	6,414,117	07-02-2002	Levinson, D. A.		
	8	6,465,185	10-15-2002	Goldfine, et al.		
	9	6,498,235	12-24-2002	Sheppard, et al.		
	10	6,562,343	05-13-2003	Levinson, D. A.		
	11	6,645,499	11-11-2003	Lal, et al.		
-	12	6,730,502	05-04-2004	Van Hijum, et al.	•	
	13	6,737,522	05-18-2004	Sundick, et al.		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ1
	14	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell, 3rd Edition</i> , pp. 403-404, 453. New York: Garland Publishing.	
	15	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , pp. 302, 363-364, 379, 435. New York: Garland Publishing.	<u>.</u> .
	16	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	
	17	GYGI, et al. Mar. 1999. Correlation between Protein and mRNA Abundance in Yeast. Molecular and Cellular Biology, 1720-1730.	
	18	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	19	HYMAN et al. Nov. 2002. Impact of DNA Amplification of Gene Expression Patterns.  Cancer Research, 62:6240-6245.	
	20	LEWIN, B. 1994. Oncogenes: Gene Expression and Cancer, Chap. 39, pp.1196-1201. Genes V. New York: Oxford University Press.	

Examiner Signature	Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

PTO/SB/08 Equivalent

	Application No.	10/063,587
INFORMATION DISCLOSURE	Filing Date	May 3, 2002
STATEMENT BY APPLICANT	First Named Inventor	Goddard et al.
STATEMENT OF APPLICANT	Art Unit	1646
(Multiple sheets used when necessary)	Examiner	Claire M. Kaufman
SHEET 2 OF 2	Attorney Docket No.	GNE.3230R1C61

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	21	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	22	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	23	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	24	ØRNTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular &amp; Cellular Proteomics</i> , 1:37-45.	
	25	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	<u> </u>
	26	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol. Annu, 1(27):165-190.	
	27	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World Journal of Surgical Oncology, 2:13.	

1528113\_1\033105

**Examiner Signature** 

**Date Considered** 

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.